# Genzyme, a Sanofi Company clinical trials: 308 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 308 trials with Genzyme, a Sanofi Company as lead sponsor, 5 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Genzyme, a Sanofi Company: 308 rows for $15.40, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/genzyme-a-sanofi-company

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 308
- Recruiting or not yet: 5
- Read on: November 19, 2026

## Trials

The 25 newest of 308, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 30, 2024 | NCT06666413 | China Post-approval Commitment (PAC) Study of Avalglucosidase Alfa in Participants With IOPD | Genzyme, a Sanofi Company | Phase 4 | Recruiting | Glycogen Storage Disease Type II, Pompe's Disease | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06666413) |
| May 20, 2024 | NCT06421714 | A Study of the Safety, Tolerability, and Pharmacokinetics of Orally Administered Venglustat and Itraconazole in Healthy Adult Male... | Genzyme, a Sanofi Company | Phase 1 | Completed | Healthy Volunteers | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06421714) |
| February 14, 2022 | NCT05238714 | Excretion Balance, Pharmacokinetics, and Metabolism Following of \[14C\]-Venglustat Administration in Healthy Male Subjects | Genzyme, a Sanofi Company | Phase 1 | Completed | Disorders of Sphingolipid Metabolism, Healthy Volunteers | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05238714) |
| December 20, 2021 | NCT05164055 | Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase) | Genzyme, a Sanofi Company | Phase 4 | Active not recruiting | Glycogen Storage Disease Type II | 17 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05164055) |
| November 26, 2021 | NCT05134571 | China Post-marketing Surveillance (PMS) Study of Aldurazyme® | Genzyme, a Sanofi Company | Phase 4 | Completed | Mucopolysaccharidosis I | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05134571) |
| September 23, 2021 | NCT05054387 | China Post-marketing Surveillance (PMS) Study of Fabrazyme® | Genzyme, a Sanofi Company | Phase 4 | Completed | Fabry Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05054387) |
| December 21, 2020 | NCT04676373 | Study to Evaluate Efficacy and Safety in Chinese Patients With Late Onset Pompe Disease With Alglucosidase Alfa Treatmen | Genzyme, a Sanofi Company | Phase 4 | Completed | Pompe's Disease | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04676373) |
| January 9, 2020 | NCT04221451 | A Multinational, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy, Pharmacodynamics, Pharmacokinetics, and Safety... | Genzyme, a Sanofi Company | Phase 3 | Terminated | Tay-Sachs Disease, Sandhoff Disease | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04221451) |
| June 4, 2019 | NCT03974113 | Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B | Genzyme, a Sanofi Company | Phase 2/3 | Completed | Hemophilia | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03974113) |
| December 24, 2018 | NCT03784898 | Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada | Genzyme, a Sanofi Company | Phase 4 | Completed | Multiple Sclerosis | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03784898) |
| December 13, 2018 | NCT03774914 | LEMTRADA Pregnancy Registry in Multiple Sclerosis | Genzyme, a Sanofi Company | Observational | Completed | Multiple Sclerosis | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03774914) |
| November 27, 2018 | NCT03754790 | Long-term Safety and Efficacy Study of Fitusiran in Patients With Hemophilia A or B, With or Without Inhibitory Antibodies to Factor VIII... | Genzyme, a Sanofi Company | Phase 3 | Completed | Hemophilia | 281 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03754790) |
| September 27, 2018 | NCT03687554 | Effect of Venglustat in Patients With Renal Impairment | Genzyme, a Sanofi Company | Phase 1 | Completed | Healthy Volunteers, Polycystic Kidney, Autosomal Dominant | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03687554) |
| September 27, 2018 | NCT03687333 | Evaluate Efficacy and Safety in Chinese Patients With Infantile-Onset Pompe Disease With One Year Alglucosidase Alfa Treatment | Genzyme, a Sanofi Company | Phase 4 | Completed | Glycogen Storage Disease Type II | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03687333) |
| June 8, 2018 | NCT03549871 | A Study of Fitusiran in Severe Hemophilia A and B Patients Previously Receiving Factor or Bypassing Agent Prophylaxis | Genzyme, a Sanofi Company | Phase 3 | Completed | Hemophilia | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03549871) |
| May 14, 2018 | NCT03523728 | A Medical Research Study Designed to Determine if Venglustat Can be a Future Treatment for ADPKD Patients | Genzyme, a Sanofi Company | Phase 2/3 | Terminated | Polycystic Kidney, Autosomal Dominant | 478 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03523728) |
| January 31, 2018 | NCT03417245 | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without Inhibitors | Genzyme, a Sanofi Company | Phase 3 | Completed | Hemophilia A, Hemophilia B | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03417245) |
| January 31, 2018 | NCT03417102 | A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors | Genzyme, a Sanofi Company | Phase 3 | Completed | Hemophilia A, Hemophilia B | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03417102) |
| December 14, 2017 | NCT03373786 | A Study of RG-012 in Subjects With Alport Syndrome | Genzyme, a Sanofi Company | Phase 1 | Completed | Alport Syndrome | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03373786) |
| December 11, 2017 | NCT03368664 | A Study to Evaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMT | Genzyme, a Sanofi Company | Phase 3 | Terminated | Multiple Sclerosis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03368664) |
| June 16, 2017 | NCT03190369 | Randomized Study of the Efficacy and Safety of a Single Dose of Synvisc-One® in Chinese Patients With Symptomatic Osteoarthritis of the Knee | Genzyme, a Sanofi Company | Phase 3 | Completed | Osteoarthritis | 440 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03190369) |
| January 12, 2017 | NCT03019406 | A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset... | Genzyme, a Sanofi Company | Phase 2 | Active not recruiting | Glycogen Storage Disease Type II-Pompe's Disease | 22 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03019406) |
| September 19, 2016 | NCT02906020 | A Global Study to Assess the Drug Dynamics, Efficacy, and Safety of Venglustat (GZ/SAR402671) in Parkinson's Disease Patients Carrying a... | Genzyme, a Sanofi Company | Phase 2 | Terminated | Parkinson's Disease | 273 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02906020) |
| August 4, 2016 | NCT02855268 | Study of Lademirsen (SAR339375) in Patients With Alport Syndrome | Genzyme, a Sanofi Company | Phase 2 | Terminated | Alport Syndrome | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02855268) |
| July 27, 2016 | NCT02845271 | Proof-of-concept Study to Assess the Efficacy, Tolerability and Safety of a Single Intraarticular Dose of GZ389988 Versus Placebo in... | Genzyme, a Sanofi Company | Phase 2 | Completed | Osteoarthritis | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT02845271) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 50 |
| Phase 1/2 | 19 |
| Phase 2 | 97 |
| Phase 2/3 | 5 |
| Phase 3 | 57 |
| Phase 4 | 39 |
| Not applicable | 14 |
| Observational | 27 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 247 |
| Terminated | 42 |
| Withdrawn | 5 |
| Recruiting | 5 |
| Approved for marketing | 3 |
| Active not recruiting | 3 |
| Unknown | 2 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Glycogen Storage Disease Type II | 33 |
| Lymphoma, Non-Hodgkin | 18 |
| Fabry Disease | 17 |
| Multiple Myeloma | 16 |
| Renal Insufficiency, Chronic | 15 |
| Carcinoma, Non-Small-Cell Lung | 13 |
| Gaucher Disease | 12 |
| Leukemia, Myeloid, Acute | 11 |
| Mucopolysaccharidosis I | 10 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 9 |
| Multiple Sclerosis, Relapsing-Remitting | 8 |
| Multiple Sclerosis | 8 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 8 |
| Crohn Disease | 7 |
| Myelodysplastic Syndromes | 7 |
| Lymphoma | 7 |
| Neoplasm Metastasis | 7 |
| Hemophilia A | 6 |
| Hyperphosphatemia | 6 |
| Osteoarthritis | 6 |
| Neoplasms | 6 |
| Thyroid Neoplasms | 6 |
| Carcinoma, Medullary | 6 |
| Leukemia | 6 |
| Enterocolitis, Pseudomembranous | 5 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Distribution companies in the United States](https://specstream.ai/data/businesses/distribution-companies/united-states)
- [Valet services in the United States](https://specstream.ai/data/businesses/valet-services/united-states)
- [Medical sciences schools in the United States](https://specstream.ai/data/businesses/medical-sciences-schools/united-states)
- [Credit and debt counseling services in the United States](https://specstream.ai/data/businesses/credit-and-debt-counseling-services/united-states)
- [Tractor dealers in the United States](https://specstream.ai/data/businesses/tractor-dealers/united-states)
- [Logging companies in the United States](https://specstream.ai/data/businesses/logging-companies/united-states)
